Recursion Pharmaceuticals, Inc., a biotechnology firm incorporated in Delaware, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on May 10, 2024. This filing pertains to the registration of additional shares of Class A common stock under the company's 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan. The registration builds upon previous filings made on April 16, 2021, May 10, 2022, and May 8, 2023. The company, which is classified as a large accelerated filer, has incorporated by reference its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and subsequent reports filed with the SEC. The documents incorporated by reference include detailed information about the company's financial performance and governance. The CEO, Christopher Gibson, along with other executives and directors, have signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.

Recursion Pharmaceuticals, Inc., a biotechnology firm incorporated in Delaware, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on May 10, 2024. This filing pertains to the registration of additional shares of Class A common stock under the company's 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan. The registration builds upon previous filings made on April 16, 2021, May 10, 2022, and May 8, 2023. The company, which is classified as a large accelerated filer, has incorporated by reference its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and subsequent reports filed with the SEC. The documents incorporated by reference include detailed information about the company's financial performance and governance. The CEO, Christopher Gibson, along with other executives and directors, have signed the registration statement, affirming the company's compliance with the requirements for filing on Form S-8.